Last updated: July 18, 2026
Litigation summary: Genentech v. Sun Pharma, 2:25-cv-11027 (what the case is about, parties, procedural posture, and why it matters)
Executive summary: GENENTECH, INC. v. SUN PHARMACEUTICAL INDUSTRIES LTD, 2:25-cv-11027 is a newly filed federal patent dispute in which Genentech is suing Sun Pharma in the District of Massachusetts over intellectual property tied to a Genentech product. At this point, the case record details needed to produce a complete litigation-and-patent-statement summary (asserted patents, FDA/Orange Book basis, causes of action, and claim construction posture) are not available in the provided information, so no litigation merits analysis can be stated without risking inaccuracies.
What are the asserted patents and claims in GENENTECH v. SUN PHARMA (2:25-cv-11027)?
Featured snippet answer: Not enough case-specific data provided to identify the asserted patent numbers, owners, and claim scope.
Which Genentech assets are being enforced (Orange Book, patents, or regulatory exclusivity)?
- The case caption alone does not identify the drug, listing, or patent family.
- Without the complaint or exhibit list, the asserted IP category (composition, formulation, method-of-use, manufacturing, polymorph, or device) cannot be mapped.
Are the claims tied to an ANDA, 505(b)(2), or biosimilar pathway?
- The procedural posture (timeline, court filings, and regulatory basis) is not identifiable from the docket number alone.
- A litigation analysis depends on whether Sun is challenging listed patents via Paragraph IV, seeking carve-outs, or asserting non-infringement/invalidity.
When was 2:25-cv-11027 filed, and what is the procedural posture?
Featured snippet answer: The filing year is 2025, but the order-by-order posture cannot be determined from the docket number alone.
Key dates that typically drive a high-stakes analysis
- Complaint filing date
- Summons/waiver and service completion
- Motion to dismiss schedule
- Preliminary injunction requests and hearing dates
- Markman schedule (if patents are asserted)
- Case management conference and discovery cutoffs
None of these dates are present in the provided input.
What relief is Genentech seeking against Sun Pharma in this case?
Featured snippet answer: No case-specific relief text is available from the provided information.
Typical relief categories in pharmaceutical patent cases
- Permanent injunction against launch
- Preliminary injunction (often paired with expedited discovery)
- Damages and/or enhanced damages under 35 U.S.C. § 284
- Attorneys’ fees under 35 U.S.C. § 285
- Corrective declarations on non-infringement/invalidity (depends on posture)
The specific requested items cannot be asserted without the complaint and prayer for relief.
How strong is Genentech’s patent estate in 2:25-cv-11027?
Featured snippet answer: Strength cannot be calculated without asserted patent numbers, remaining term, and claim scope.
What an evidence-based strength assessment requires
- Patent grant dates and expiration windows
- Whether patents are primary (listed in Orange Book) or secondary
- Reexamination/prosecution history and claim amendments
- Prior enforcement and litigation outcomes by the same family
No patent identifiers or family structure are provided.
What generic entry risks exist for Sun Pharma if it loses (or wins) 2:25-cv-11027?
Featured snippet answer: Entry-risk mapping requires the asserted Orange Book listing, Sun’s application number, and any FDA approval/launch timelines.
Scenario analysis framework (cannot be populated)
- If a listed patent is found infringed and not invalid, launch is typically barred until patent expiry or a settlement carve-out.
- If patents are invalidated or not infringed, FDA may permit earlier market entry depending on approval status and remaining exclusivities.
No application or drug identification is included.
Which patents are likely challenged via Paragraph IV or non-infringement defenses in this case?
Featured snippet answer: The Paragraph IV/non-infringement landscape cannot be determined without the FDA/Orange Book basis.
What defendants typically argue in ANDA-related disputes
- Non-infringement by manufacturing changes or claim interpretation
- Invalidity based on anticipation/obviousness and enablement issues
- Indefiniteness or lack of written description
- Inequitable conduct (rare but consequential)
No asserted grounds are provided.
Does the case include Hatch-Waxman 30-month stay issues or FDA timing disputes?
Featured snippet answer: Unknown.
Timing variables that drive stay and damages
- Whether Sun filed a notice under § 505(j)
- Whether 30-month stay is in effect or has expired
- Whether an FDA approval occurred and whether “at-risk” launch took place
- Whether there is a settlement triggering licensed launch dates
The docket number does not supply this information.
What is the likelihood of settlement in Genentech v. Sun Pharma (2:25-cv-11027)?
Featured snippet answer: Cannot be assessed from the provided information.
Settlement indicators that require record access
- Early filing of stipulations or consent orders
- Confidential settlement announcements
- On-the-record mediation and schedule changes
- Narrowing of asserted claims
No such indicators are included in the input.
What other related litigation involving the same Genentech patents or Sun Pharma products could affect outcomes?
Featured snippet answer: Not identifiable from the docket number alone.
Cross-case patterns that matter
- Judges in the District of Massachusetts often coordinate similar Hatch-Waxman cases by same patent family
- Common claim constructions recur across cases
- Indirect estoppel or issue preclusion depends on final judgments and timing
No related cases are provided.
Key Takeaways
- 2:25-cv-11027 is a GENENTECH v. SUN PHARMA federal patent litigation, but case-specific allegations and asserted patent details are not provided, preventing an accurate infringement/validity/entry-risk analysis.
- A credible “litigation summary and analysis” requires the complaint’s asserted patent list, the FDA/Orange Book linkage, and procedural orders, none of which are contained in the current input.
FAQs
- What is the assigned judge and magistrate in 2:25-cv-11027?
- Which patents did Genentech assert in its complaint against Sun Pharma in this case?
- Was the case filed under Hatch-Waxman with an ANDA Paragraph IV theory?
- Has Sun Pharma launched “at risk” for the product associated with this docket?
- What claim construction timetable is set for 2:25-cv-11027 and when is the Markman hearing?
References (APA)
- GENENTECH, INC. v. SUN PHARMACEUTICAL INDUSTRIES LTD, No. 2:25-cv-11027 (D. Mass.).
